The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis
Sign Up to like & getrecommendations! Published in 2023 at "Medicine"
DOI: 10.1097/md.0000000000032591
Abstract: Background: The efficacy of tivantinib for MET-high hepatocellular carcinoma remains controversial. We conduct this meta-analysis to explore the efficacy of tivantinib versus placebo for MET-high hepatocellular carcinoma. Methods: We have searched PubMed, EMbase, Web of… read more here.
Keywords: met high; hepatocellular carcinoma; meta analysis; high hepatocellular ... See more keywords
Second-line tivantinib (ARQ 197) vs placebo in patients (Pts) with MET-high hepatocellular carcinoma (HCC): Results of the METIV-HCC phase III trial.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.4000
Abstract: 4000Background: Tivantinib (T), a selective, oral MET inhibitor, improved overall survival (OS) and progression-free survival (PFS) versus placebo (P) in a phase II study in MET-High HCC pts. Metho... read more here.
Keywords: phase; hcc; line tivantinib; placebo ... See more keywords